IP Library Granted Patent US 12,324,787
Granted Patent B1
US 12,324,787 · App. 18/905,498 · Granted Jun 10, 2025

Kits for preparing and delivering purified corticotropin

Inventors: Edward M. DeSimone, III (Indianapolis, IN); Weijun Cheng (Middleton, WI); Zachary Holcomb (Waunakee, WI)
Assignee: ANI Pharmaceuticals, Inc.
A61J1/1443A61J1/065A61K38/35A61K47/10A61K47/42
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,324,787
App. No.
18/905,498
Granted
Jun 10, 2025
Kind
B1
Abstract

A kit and sterile preparation of purified corticotropin and methods relating thereto in which the preparation includes corticotropin extracted from a whole porcine pituitary gland including both anterior and posterior portions, and having proteins or peptides having a molecular weight higher than 4.6 kDa removed. Methods of manufacturing, testing, increasing stability, storage, and use of the purified corticotropin are also provided.

Claims (21)

1. A kit comprising a vial and a sterile preparation of purified corticotropin, wherein the sterile preparation comprises 80 USP units per mL of corticotropin, phenol, type A gelatin, water for injection (WFI), hydrochloric acid, and sodium hydroxide, wherein the vial is not terminally sterilized, and

wherein the purified corticotropin comprises a polypeptide having an amino acid sequence of SYSMEHFRWGKPVGKKRRPVKVYPNGAEDELAEAFPLEF (SEQ ID NO: 1).

2. The kit of claim 1 , further comprising instructions for using a first needle having a first gauge size with a first diameter to draw up the sterile preparation, and for injecting the sterile preparation using a second needle having a second gauge size with a second diameter.

3. The kit of claim 1 , wherein the vial is a 5 mL multiple-dose vial.

4. The kit of claim 2 , wherein the first diameter is wider than the second diameter.

5. The kit of claim 2 , wherein the first gauge size is 20 G and the second gauge size is 23 G.

6. The kit of claim 1 , wherein the sterile preparation comprises 0.5% w/w phenol, 15.0% w/w gelatin, and water for injection (WFI).

7. The kit of claim 1 , wherein the sterile preparation comprises hydrochloric acid and sodium hydroxide.

8. The kit of claim 1 , wherein the sterile preparation has a pH of 3.0-7.0.

9. The kit of claim 1 , wherein the sterile preparation comprises purified corticotropin comprises an extract from whole porcine pituitary gland including both anterior and posterior portions of the whole porcine pituitary gland, 0.5% w/w phenol, 15% w/w gelatin type A, and water for injection (WFI).

10. The kit of claim 1 , wherein the sterile preparation comprises about 15% w/w of the type A gelatin.

11. The kit of claim 1 , wherein the sterile preparation comprises about 150 mg/ml of the type A gelatin.

12. The kit of claim 10 , wherein the sterile preparation comprises about 0.1-1% w/w of the phenol.

13. The kit of claim 12 , wherein the sterile preparation comprises about 0.5% w/w of the phenol.

14. The kit of claim 11 , wherein sterile preparation comprises about 5 mg/ml of the phenol.

15. The kit of claim 1 , wherein the kit further comprises instructions for use including washing hands and drying with a clean towel, removing the vial from a refrigerator, confirming that an expiration date on the vial has not passed, warming the gel in the vial from a solid gel to a liquid gel by rolling between hands for at least one minute, removing plastic cap from the top of the vial, wiping top of the vial stopper with a sterile alcohol wipe, using a sterile 20 G needle and syringe to draw up the warmed purified cortrophin gel from the vial, removing the 20 G needle, attaching a 23 G needle to the syringe, injecting the warmed purified cortrophin gel from the syringe into the subject.

16. The kit of claim 1 , wherein the sterile preparation is preservative-free, antimicrobial-free, or preservative-free and antimicrobial-free.

17. The kit of claim 1 , wherein the gelatin has a pH of 5.9 to 6.2.

18. The kit of claim 1 , wherein the sterile preparation is free of acetic acid.

19. The kit of claim 1 , wherein the gelatin is pyrogen-free.

20. The kit of claim 1 , wherein the sterile preparation comprises acidified WFI having a pH of 2.8 to 3.2.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2024
From: DESIMONE III, EDWARD M.; CHENG, WEIJUN; HOLCOMB, ZACHARY
To: ANI PHARMACEUTICALS, INC.
Reel/Frame 069717/0424 →
Continuity (2)
Continuation 18496150 · Oct 27, 2023
Provisional Application 63381451 · Oct 28, 2022
References Cited (41)
US 2992165A · Thompson · 1961 [cited by applicant]
US 4374063A · Consolazio · 1983 [cited by applicant]
US 6461334B1 · Buch-Rasmussen · 2002 [cited by applicant]
US 10232018B2 · Knight et al. · 2019 [cited by applicant]
US 10286041B2 · Cartt · 2019 [cited by applicant]
US 11752199B1 · Wright · 2023 [cited by applicant]
US 11975047B1 · DeSimone, III · 2024 [cited by applicant]
US 12102662B1 · DeSimone, III · 2024 [cited by applicant]
US 20070054957A1 · Upadhyay · 2007 [cited by applicant]
US 20090216212A1 · Fangrow, Jr. · 2009 [cited by applicant]
US 20140294923A1 · Cartt et al. · 2014 [cited by applicant]
US 20180161243A1 · Ariagno · 2018 [cited by applicant]
US 20180250365A1 · Somera-Molina · 2018 [cited by applicant]
US 20190160150A1 · Knight et al. · 2019 [cited by applicant]
US 20190216901A1 · Cartt et al. · 2019 [cited by applicant]
US 20210100878A1 · Lollo et al. · 2021 [cited by applicant]
US 20210322520A1 · Wright · 2021 [cited by applicant]
US 20220031611A1 · Bansal · 2022 [cited by applicant]
US 20220054595A1 · Lollo et al. · 2022 [cited by applicant]
US 20220111012A1 · Wright et al. · 2022 [cited by applicant]
US 20220133595A1 · Miksztal · 2022 [cited by applicant]
US 20230165946A1 · Rhee · 2023 [cited by applicant]
WO 2020150738A1 · 2020 [cited by applicant]
WO 2022131919A1 · 2022 [cited by applicant]
WO 2023034819A1 · 2023 [cited by applicant]
Office Action dated Oct. 16, 2024 issued in U.S. Appl. No. 18/818,974. (24 pages). [cited by applicant]
Mallinckrodt (ACTHAR—repository corticotropin injection, Injection Instructions; ARDUS/01-13/0417/0033, 2017. [cited by applicant]
Mallinckrodt Label—NIH/DailyMed. Drug Archives, 2016 label. [cited by applicant]
Citron Reports Further Results from Laboratory Testing: Questcor is Deceiving the FDA and Investors, H.P. Acthar Gel's Specified Active Ingredient Less Than 20% of the Label Specification, Bioactivity of Deamidated Horm… [cited by applicant]
Acthar Gel (repository corticotropin injection), Package Insert, Mallinckrodt ARD LLC, 2021, 22 pgs. [cited by applicant]
Repository Corticotropin (H.P. Acthar Gel), BlueCross BlueShield of North Carolina, 2012, 5 pgs. [cited by applicant]
Purified Cortrophin(R) Gel Repository Corticotropin Injection U.S.P., Organon Inc., (1972), 3 pgs. [cited by applicant]
USP, Notice of Intent to Revise:<660> Container Glass, (Year:2023) (2 pages). [cited by applicant]
Office Action issued in U.S. Appl. No. 18/495,932 dated Jan. 11, 2024 (27 pages). [cited by applicant]
Office Action issued in U.S. Appl. No. 18/496,170 dated Sep. 25, 2024 (13 pages). [cited by applicant]
Wallace I, Cunningham S, Lindsay J. The diagnosis and investigation of adrenal insufficiency in adults. Ann Clin Biochem. Sep. 2009;46(Pt 5):351-67. (Year: 2009) 17 pgs. [cited by applicant]
Office Action dated Mar. 13, 2024 issued in corresponding U.S. Appl. No. 18/496,150 (9 pages) [cited by applicant]
Mallinckrodt, Acthar: Step-by-Step Self-Injection Instructions (repository corticotropin injection), 2017 (28 pages). [cited by applicant]
Mallinckrodt Label—NIH/DailyMed. Drug Archives, 2016 label (18 pages). [cited by applicant]
Acthar Gel, repository corticotropin injection. Package Insert. Mallinckrodt ARD. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/008372s068lbl.pdf (Revised Feb. 2021… [cited by applicant]
Riniker et al. Revised amino-acid sequences for porcine and human adrenocorticotrophic hormone. Nat New Biol. Jan. 26, 1972;235(56):114-5. [cited by applicant]
Cited By (1)
US 12,734,217